Expansion of Overseas Reagent Production Capacity
First written in FY2016. 3 of 7 entries say "Restated". Latest entry: FY2026.
1 other company's latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「In India, our new production site equipped with the group's first production functions for both diagnostic reagents and instruments in response to the Make in India policy and other requirements has entered full-scale operation, and local production is under way.」
The project progressed from the construction-completed stage disclosed previously to the stage where the new site is fully operational and local production of diagnostic reagents and instruments has begun. - FY2025-H1AdvancedAnnual report
「Under these circumstances, we completed construction of a new production site in India equipped with the group's first production functions for both reagents and instruments. This new site has the largest total floor area of the group's overseas production facilities, substantially expands the range of reagents produced, and has the capability to manufacture instruments in response to the Make in India policy.」
Construction of the new site in India, which produces both reagents and instruments, was completed, expanding the range of reagents produced and establishing instrument production capabilities in response to the Make in India policy. Shipment commencement was planned during the fiscal year ending March 2025. - FY2018RestatedAnnual report
「We completed the expansion of our US reagent production plant, undertaken to meet future growth in demand for reagents in the Americas and ensure a stable supply over the medium to long term. As a result, production capacity is now 1.8 times its previous level. We will continue to supply products reliably through production systems tailored to market conditions in each region.」
The company has reiterated the completion of the US reagent production plant expansion, the 1.8-fold increase in production capacity, and its policy of ensuring a stable supply tailored to market conditions in each region. - FY2018-Q3RestatedAnnual report
「We completed the expansion of our US reagent production plant, undertaken to meet future growth in demand for reagents in the Americas and ensure a stable supply over the medium to long term. As a result, production capacity is now 1.8 times its previous level. The group has produced reagents locally at 2 sites in Japan and 7 sites in 6 overseas countries, and will continue to supply products reliably through production systems tailored to market conditions in each region.」
The company has continued to disclose the completion of the US plant expansion, the 1.8-fold increase in production capacity, its local production structure in Japan and overseas, and its stable supply policy from the previous quarter. - FY2018-Q2AdvancedAnnual report
「We completed the expansion of our US reagent production plant, undertaken to meet future growth in demand for reagents in the Americas and ensure a stable supply over the medium to long term. As a result, production capacity is now 1.8 times its previous level. The group has produced reagents locally at 2 sites in Japan and 7 sites in 6 overseas countries, and will continue to supply products reliably through production systems tailored to market conditions in each region.」
The US reagent production plant expansion was completed, increasing production capacity to 1.8 times its previous level. The company also disclosed its local production structure at 2 sites in Japan and 7 sites in 6 overseas countries, as well as its policy of ensuring a stable supply. - FY2017RestatedAnnual report
「The main components of capital expenditure were the expansion of reagent production plants at overseas subsidiaries to increase production volumes of reagents for specimen testing in line with business expansion in overseas markets, as well as the acquisition of equipment to be loaned to customers.」
The company has reiterated the expansion of reagent production plants at overseas subsidiaries and the acquisition of equipment for loan to customers as capital expenditure results. - FY2016First statedAnnual report
「To meet expected future growth in demand in the EMEA region, we completed the expansion of our reagent production plant in Germany, increasing production capacity to approximately 1.5 times its previous level. In the Americas, we began expanding our US reagent production plant to respond to expected future growth in demand for reagents and ensure a stable supply.」
The expansion of the German plant was completed, increasing capacity to approximately 1.5 times its previous level, while expansion of the US plant began.